Evidence map›Paper›PMID 42766724›Full record

ArticleJMIR dermatology2026

Current Management and Unmet Needs in Alopecia Areata: Viewpoint From a Malaysian Perspective.

Azura Mohd Affandi, Adawiyah Jamil, Noor Zalmy Azizan, Felix Boon-Bin Yap, Kin Fon Leong, Agnes Yoke Hui Heng, Siti Nuraihan, Wooi Chiang Tan, Latha Selvarajah, Teeba Raja and 4 more

Abstract read
In one paragraph

Article in JMIR dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Azura Mohd AffandiDepartment of Dermatology, Ministry of Health, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.ORCID 0000-0003-1323-0078
Adawiyah JamilFaculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.ORCID 0000-0002-8683-7535
Noor Zalmy AzizanCentral Dermatology Specialist Clinic, Kuala Lumpur, Malaysia.ORCID 0009-0004-3781-4662
Felix Boon-Bin YapSunway Medical Centre, Selangor, Malaysia.ORCID 0000-0002-8658-1912
Kin Fon LeongDermatology Unit, Hospital Tunku Azizah, Kuala Lumpur, Malaysia.ORCID 0000-0002-1984-7960
Agnes Yoke Hui HengAgnes Heng Dermatology, Ipoh, Malaysia.ORCID 0000-0003-4732-5251
Siti NuraihanPediatric Dermatology Unit, Pediatric Department, Ministry of Health, Hospital Selayang, Selangor, Malaysia.ORCID 0000-0002-6590-8680
Wooi Chiang TanDepartment of Dermatology, Ministry of Health, Hospital Pulau Pinang, Pulau Pinang, Malaysia.ORCID 0000-0003-0724-0974
Latha SelvarajahDepartment of Dermatology, Ministry of Health, Hospital Sultan Ismail, Johor Bahru, Malaysia.ORCID 0000-0002-4821-7474
Teeba RajaDepartment of Dermatology, Ministry of Health, Hospital Selayang, Selangor, Malaysia.ORCID 0000-0003-0669-8609
Evelyn Wen Yee YapDepartment of Dermatology, Mahkota Medical Centre, Melaka, Malaysia.ORCID 0000-0003-4228-4673
Peter Wee Beng Ch'ngDepartment of Dermatology, Gleneagles Hospital, Kuala Lumpur, Malaysia.ORCID 0000-0002-1266-5769
Tze Yuen TeohCentral Dermatology Specialist Clinic, Kuala Lumpur, Malaysia.ORCID 0009-0000-5595-2621
Mei Ying TeyMedical Affairs, Pfizer, Level 10 & 11, Wisma Averis, Tower 2, Avenue 5, Bangsar South, No 8, Jalan Kerinchi, Kuala Lumpur, Malaysia.ORCID 0009-0001-4952-1224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlabelled: Alopecia areata (AA) is a chronic, immune-mediated disease characterized by nonscarring hair loss and a substantial clinical and psychosocial burden, yet it is still widely perceived as a purely cosmetic concern. In this viewpoint, we draw on the available Malaysian studies, selected international evidence, and our collective clinical experience to propose that AA warrants greater clinical, research, and policy attention in Malaysia. Malaysia-specific evidence remains limited and is derived largely from retrospective, single-center studies; nonetheless, the available data point to variable disease presentation, inconsistent use of standardized severity assessment, reliance on conventional therapies, substantial loss to follow-up, and a meaningful psychosocial impact among affected patients. Current local management appears to rely mainly on conventional therapies, while access to advanced therapies such as Janus kinase inhibitors remains constrained by affordability and reimbursement challenges. We therefore call for 5 priorities: strengthening Malaysia-specific epidemiological and real-world evidence, including through a national AA registry; adopting standardized disease-assessment tools in clinical studies and routine practice; integrating psychosocial support into AA care pathways; developing locally relevant clinical guidance; and improving public, clinician, and policymaker awareness that AA is a medical condition rather than a cosmetic concern. Together, these steps would support earlier diagnosis, more equitable access to effective treatment, and holistic, patient-centered care for adults and children living with AA in Malaysia.

Indexed as

Alopecia AreataHumansMalaysiaalopeciaalopecia areataJAK inhibitorsJanus kinase inhibitorsMalaysiareimbursement

Identifiers

PMID42766724
PMCPMC13592563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.